Screening for attention-deficit/hyperactivity disorder traits among adults living with HIV or taking pre-exposure prophylaxis in Switzerland: a cross-sectional survey nested within the Swiss HIV Cohort Study and SwissPrEPared - a study protocol
- 1Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, Basel, Switzerland
Abstract
IntroductionPeople living with HIV experience disproportionately high rates of mental health conditions, yet adult attention-deficit/hyperactivity disorder (ADHD) is largely absent from the HIV literature. Traits associated with ADHD, together with social exclusion, adverse life events, stigma, and barriers to accessing healthcare may increase vulnerability to HIV acquisition and complicate adherence to treatment and prevention, and a comparable pathway may apply to users of HIV pre-exposure prophylaxis (PrEP). Prevalence data on ADHD in people living with HIV are limited to two small-scale studies, and no data exist for PrEP users. The objective of this study is to estimate the prevalence of ADHD traits among people living with HIV and PrEP users in Switzerland and to describe sociodemographic, behavioural and clinical patterns. The study was co-created and is co-led by people who, beyond their academic and clinical practices, have experiential knowledge of the topics being explored
Methods and analysisThis is a multicentre cross-sectional survey using a Critical ADHD Studies framework and nested within the Swiss HIV Cohort Study (SHCS) and SwissPrEPared cohort. Over a 12-month recruitment period, participants attending routine visits at participating sites will complete the six-item Adult ADHD Self-Report Scale Screener (ASRS-5). A positive screen is defined as a weighted score of 14 or higher. Three additional items capture the presence of traits in childhood before the age of 12, any previously established ADHD diagnosis, and the participants wish to receive their score and/or a follow-up consultation with a psychologist or psychiatrist. Screening data will be linked to routinely collected cohort variables. The primary objective is to estimate the prevalence of a positive ASRS-5 screen, with 95% Wilson score confidence intervals, in each cohort. Secondary objectives include comparing cohorts and examining associations between ADHD traits and substance use, sexual behaviour, sexually transmitted infections, depression and anxiety, treatment and prevention adherence, use of and interest in long-acting HIV treatment modalities, and gender identity and sexual orientation. A target sample of 800 participants per cohort was calculated for a 3% prevalence margin of error.
Ethics and disseminationThe study is nested within the SHCS and SwissPrEPared and falls under their existing ethical approvals and general participant consent. Participants who screen positive and wish to be followed up will be offered a consultation with an ADHD-experienced psychologist or psychiatrist. Results will be publicly available on the study website, published in peer-reviewed journals, and shared with participants and communities through lay summaries and cohort communication channels.
STRENGTHS AND LIMITATIONS OF THIS STUDY The first study to systematically estimate the prevalence of ADHD traits at scale among people living with HIV and among users of HIV pre-exposure prophylaxis (PrEP). Systematic administration to all participants attending routine visits, embedded in existing cohort workflows, limiting self-selection and reducing participation bias. Linkage to rich, routinely collected cohort data allowing exploration of a broad range of sociodemographic, behavioural, and clinical correlates at scale. The ASRS-5 identifies ADHD traits rather than making a clinical diagnosis; the study therefore estimates screening-positive trait prevalence, expected to exceed the possible prevalence of ADHD diagnoses, as in the general population. Differences in questionnaire administration between cohorts (provider-administered in the SHCS versus self-administered in SwissPrEPared) and incomplete harmonisation of some variables may limit between-cohort comparability, resulting in cohort-stratified analyses instead.
Related
- Screening of Attention-Deficit Hyperactivity Disorder and its associated factors among medical university students in Lebanon: A multicenter cross-sectional study
- Screen time and attention-deficit/hyperactivity disorder in children: a systematic review and meta-analysis
- Attention-deficit/hyperactivity disorder and odds of subsequent multiple sclerosis: a population-based retrospective case–control study
- Interpretable attention-deficit hyperactivity disorder diagnosis from functional magnetic resonance imaging via hybrid convolutional neural network–transformer learning and multi-level graph-based comprehensibility
- QuickStats: Percentage* of Children and Adolescents Aged 5–17 Years Who Had Ever Received a Diagnosis of Attention-Deficit/Hyperactivity Disorder, by Sex and Year — United States, 2019–2025
BibTeX
@misc{jacksonperry2026screening,
title = {{Screening for attention-deficit/hyperactivity disorder traits among adults living with HIV or taking pre-exposure prophylaxis in Switzerland: a cross-sectional survey nested within the Swiss HIV Cohort Study and SwissPrEPared - a study protocol}},
author = {D. Jackson-Perry and S. Campos Ochoa and S. Corbisiero and I. A. Abela and G. H. Yoon and M. Cavassini and B. Hampel and A. Amstutz and the Swiss HIV Cohort Study and the SwissPrEPared Cohort Study},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.08.26362490},
url = {https://www.medrxiv.org/content/10.64898/2026.09.08.26362490v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Screening for attention-deficit/hyperactivity disorder traits among adults living with HIV or taking pre-exposure prophylaxis in Switzerland: a cross-sectional survey nested within the Swiss HIV Cohort Study and SwissPrEPared - a study protocol
AU - D. Jackson-Perry
AU - S. Campos Ochoa
AU - S. Corbisiero
AU - I. A. Abela
AU - G. H. Yoon
AU - M. Cavassini
AU - B. Hampel
AU - A. Amstutz
AU - the Swiss HIV Cohort Study
AU - the SwissPrEPared Cohort Study
PY - 2026
DA - 2026/09/08
PB - medRxiv
DO - 10.64898/2026.09.08.26362490
UR - https://www.medrxiv.org/content/10.64898/2026.09.08.26362490v1
AB - IntroductionPeople living with HIV experience disproportionately high rates of mental health conditions, yet adult attention-deficit/hyperactivity disorder (ADHD) is largely absent from the HIV literature. Traits associated with ADHD, together with social exclusion, adverse life events, stigma, and barriers to accessing healthcare may increase vulnerability to HIV acquisition and complicate adherence to treatment and prevention, and a comparable pathway may apply to users of HIV pre-exposure prophylaxis (PrEP). Prevalence data on ADHD in people living with HIV are limited to two small-scale studies, and no data exist for PrEP users. The objective of this study is to estimate the prevalence of ADHD traits among people living with HIV and PrEP users in Switzerland and to describe sociodemographic, behavioural and clinical patterns. The study was co-created and is co-led by people who, beyond their academic and clinical practices, have experiential knowledge of the topics being explored Methods and analysisThis is a multicentre cross-sectional survey using a Critical ADHD Studies framework and nested within the Swiss HIV Cohort Study (SHCS) and SwissPrEPared cohort. Over a 12-month recruitment period, participants attending routine visits at participating sites will complete the six-item Adult ADHD Self-Report Scale Screener (ASRS-5). A positive screen is defined as a weighted score of 14 or higher. Three additional items capture the presence of traits in childhood before the age of 12, any previously established ADHD diagnosis, and the participants wish to receive their score and/or a follow-up consultation with a psychologist or psychiatrist. Screening data will be linked to routinely collected cohort variables. The primary objective is to estimate the prevalence of a positive ASRS-5 screen, with 95% Wilson score confidence intervals, in each cohort. Secondary objectives include comparing cohorts and examining associations between ADHD traits and substance use, sexual behaviour, sexually transmitted infections, depression and anxiety, treatment and prevention adherence, use of and interest in long-acting HIV treatment modalities, and gender identity and sexual orientation. A target sample of 800 participants per cohort was calculated for a 3% prevalence margin of error. Ethics and disseminationThe study is nested within the SHCS and SwissPrEPared and falls under their existing ethical approvals and general participant consent. Participants who screen positive and wish to be followed up will be offered a consultation with an ADHD-experienced psychologist or psychiatrist. Results will be publicly available on the study website, published in peer-reviewed journals, and shared with participants and communities through lay summaries and cohort communication channels. STRENGTHS AND LIMITATIONS OF THIS STUDY The first study to systematically estimate the prevalence of ADHD traits at scale among people living with HIV and among users of HIV pre-exposure prophylaxis (PrEP). Systematic administration to all participants attending routine visits, embedded in existing cohort workflows, limiting self-selection and reducing participation bias. Linkage to rich, routinely collected cohort data allowing exploration of a broad range of sociodemographic, behavioural, and clinical correlates at scale. The ASRS-5 identifies ADHD traits rather than making a clinical diagnosis; the study therefore estimates screening-positive trait prevalence, expected to exceed the possible prevalence of ADHD diagnoses, as in the general population. Differences in questionnaire administration between cohorts (provider-administered in the SHCS versus self-administered in SwissPrEPared) and incomplete harmonisation of some variables may limit between-cohort comparability, resulting in cohort-stratified analyses instead.
ER -